As An Enabler of Personalized Therapeutics, Companion Diagnostics Witnesses Unprecedented Development & Commercialization Efforts
Growing role of personalized medicine and
theranostics in disease treatment is poised to drive the global market for Companion
Diagnostics to reach US$5.8 billion by 2022. A Companion Diagnostic (CDx) refers to a
diagnostic test used as a companion to a therapeutic drug for increased
efficacy of the drug and for pre-determining the efficacy of the treatment. CDx
are usually in-vitro devices or assays or imaging tools, which are developed
during development of the corresponding drug or after the drug is on the
market. By providing crucial information on an individual’s risk factors for
hard-to-diagnose conditions, and also predicting safety and efficacy of the
drug in relevance to the targeted patient group, companion diagnostics enable
healthcare professionals to decide whether a drug’s benefits outweigh its
risks. They help doctors in appropriate dosage of medication, determine how
well a patient is responding to a prescribed therapy, and also analyze risk of
recurrence of a disease. Use of CDx during drug development and clinical trials
increases the success rate of drugs, because they can identify patient sub-groups
that are most likely to respond to a certain treatment and thus guide therapy
decisions and improve patient outcomes, in turn reducing healthcare
expenditure.
Companion diagnostics have ushered the emergence of personalized medicine, a breakthrough approach in
the clinical treatment process. Companion diagnostics evaluate the safety and
efficacy of a drug as well as optimum dosage for treating a patient, thereby
paving the way for the practice of personalized medicine. Collaborations and
partnerships between pharmaceutical companies and diagnostic technology
providers are resulting in simultaneous approval of drugs and their
corresponding companion diagnostics. In terms of technology, Next-Generation Sequencing
(NGS) is
expected to boost the CDx market, on account of its capability to identify
multiple genes simultaneously and yield superior results. Oncology represents
the leading application area for companion diagnostic development, with most of
the FDA-approved companion diagnostics developed for breast cancer, lung
cancer, gastric cancer, colorectal cancer, and melanoma. Breast cancer,
especially, has been the highest revenue grosser, because most CDx were
developed to detect the HER/neu biomarker for breast cancer. Neurology
represents a therapeutic area with rapid growth potential, owing to unmet medical
needs and extensive R&D in therapies for Alzheimer’s and Parkinson’s
disease.
As
stated by the new market research report on Companion Diagnostics, the United States
represents the largest market worldwide. Asia-Pacific ranks as the fastest
growing market, with a CAGR of 17% over the analysis period. The growth in the
region is led by growing population, prevalence of diseases, increased spending
on healthcare R&D by governments, migration to value based healthcare and
higher per capita healthcare spending by the growing base of affluent middle
class population.
Major players in the market include Abbott
Molecular, Agilent Technologies Inc., bioMérieux SA, Cepheid, Danaher
Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine Inc., Laboratory
Corporation of America® Holdings, Leica Biosystems Nussloch GmbH, Merck &
Co. Inc., Myriad Genetics Inc., NeoGenomics Inc., QIAGEN N.V., Quest
Diagnostics Inc., and Thermo Fisher Scientific Inc., among others.
The research report titled
"Companion Diagnostics -
Market Analysis, Trends, and Forecasts" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth
drivers, mergers and acquisitions, and other strategic industry activities of
major companies worldwide. The report provides market estimates and projections
for geographic markets, such as the US, Canada, Japan, Europe (France, Germany,
Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China and Rest of
Asia-Pacific), Latin America, and Rest of World. Application areas analyzed for
the global market include Oncology, Neurology, and Others (including
Cardiovascular and Gastrointestinal therapy areas).
For
enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.
For cutting edge analyst reviews on top industries
Follow
us on Twitter; Connect with us on
LinkedIn;
Follow us on Medium
Comments
Post a Comment